Radio and PodcastLive Radio & PodcastsOpening Radio and Podcast...
Radio and PodcastLive Radio & PodcastsFetching podcast shows and categories...
Radio and PodcastLive Radio & PodcastsFetching podcast episodes...
Independent and targeted hematology/oncology news for cancer patient care team; breaking clinical news; oncology analysis and commentary; professional trends.
In this episode of OncTimes Talk, we chat with Tom Hulsey—athlete, author, and prostate cancer survivor—about the life-altering moment he re...
In this third episode of the OncoExTra® podcast series, host Ruchika Talwar, MD, talks with Christy Russell, MD, Vice President of Medical A...
In this episode of OncTimes Talk, we chat with Sami Mansfield, ACSM-CET, PN1, the founder of Cancer Wellness for Life, an organization dedic...
In this episode of OncTimes Talk, we chat with Katie Coleman. Diagnosed with an ultra-rare stage IV kidney cancer in 2020 , her prognosis ha...
In this podcast episode, host Ruchika Talwar, MD, is joined by Amin Mazloom, PhD, Senior Vice President of Bioinformatics, Biostatistics & D...
In this episode, Dr. Ruchika Talwar, a urologic oncologist at Vanderbilt University Medical Center, Dr. Adham Jurdi, a medical oncologist an...
In this episode of the OncTimes Talk, we chat with Susan MacDonald, MD, Associate Professor and Program Director of the Department of Urolog...
Masood Moghul, MBBS, a urologist and Research Fellow at the Royal Marsden Hospital and Institute of Cancer Research in London shared finding...
At the 2025 ASCO Genitourinary Cancers Symposium, researchers from Japan reported marked differences between the populations of several key...
At the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, the Phase III AFU-GETUG-20 trial reported that adjuvant androgen deprivat...
A numerical formula called the absolute percentage pattern 4/5 (APP4) combining risk factors, including Gleason grade, PSA, and digital rect...
Masood Moghul, MBBS, a urologist and research fellow at the Royal Marsden Hospital and Institute of Cancer Research in London, UK, discussed...
In the third episode of A Deep Dive Into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking...
In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speakin...
In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking...
The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings fr...
Although one in five colorectal cancers having microsatellite instability and expressing the Werner Helicase (WRN) gene could be treated wit...
A tumor-agnostic classifier and screening tool was announced at ESMO Congress 2024 in Barcelona. It was created to make it easier and quicke...
Findings from a study of patients receiving targeted therapy for their BRAFV600 mutation-positive advanced melanoma, suggest that switching...
The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings fr...
A clinically meaningful benefit in overall survival was found in the second interim analysis of the randomized, double-blind, Phase III KEYN...
In this podcast episode, Ruchika Talwar, MD, sits down with Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences...
The prospect of markedly raising chemotherapy response rates and extending patient survival has been held out by scientists reporting a new...
The prospect of a minimally toxic, chemotherapy-free cure for hepatoblastoma is held out by findings from a mouse model using the small-mole...
A chemotherapy-free combination of two anti-human epidermal growth factor receptor 2 (anti-HER2) agents brought clinically meaningful respon...
The fibroblast growth factor receptor-3 (FGFR-3) inhibitor TYRA-300 has been found safe with dose-dependent responses and disease control in...
The mini-protein radiopharmaceutical AKY-1189, designed to deliver the alpha-emitting isotope Actinium-225 (225Ac) to tumors expressing the...
In a Phase I study with 318 patients in China and Australia the antibody-drug conjugate (ADC) IBI354 was found to be safe and have promising...
Sustained responses and long-term overall survival have resulted from checkpoint inhibitor therapy for advanced melanoma, transforming the p...
The addition of preoperative chemoradiation therapy to perioperative chemotherapy did not improve overall survival as compared with perioper...
Patients with muscle-invasive bladder cancer experienced “clinically meaningful” improvements in key outcomes—event-free survival and overal...
When patients with recurrent high-grade glioblastoma were treated with autologous myeloid dendritic cells, they had clinical responses descr...
Patients with newly diagnosed, surgically resected MGMT-unmethylated glioblastoma may benefit from treatment with a therapeutic mRNA vaccine...
A large, expanded-cohort pooled analysis of neoadjuvant immunotherapy for patients with resectable Stage III melanoma has reported very high...
Drug resistance can be delayed and treatment outcomes predicted in patients with ovarian cancer with the help of relatively low-cost molecul...
Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the E...
The escalating danger of cardiac toxicity posed by a range of increasingly effective anti-cancer therapies is insufficiently understood, acc...
Details of the expanding range of cell therapies beyond hematologic malignancy were reported at the 2024 Annual Meeting of the Chinese Socie...
An assessment of progress with antibody-drug conjugates (ADCs) for the treatment of HER2-dependent metastatic breast cancer was given at the...
At the opening session of the Chinese Society of Clinical Oncology (CSCO) 2024 Annual Meeting, attended by nearly 30,000 cancer specialists,...
Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the 2...
A large international cohort study has found that women testing positive for the BRCA mutation who chose to breastfeed their babies after tr...
Women who chose to interrupt their endocrine therapy after their breast cancer surgery to have a baby faced no additional cancer risk, accor...
Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the E...
HPV vaccination for girls and boys in the United States has led to a real-world reduction of oral head and neck cancers in men, as well as t...
Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid...
Patients who had immune-related adverse events had better responses and lived longer than those who didn’t. This was a real-world observatio...
A mathematical model using data from routine diagnostic samples has been found to accurately predict individual patient responses to the mai...
When the mucin-1 (MUC-1) vaccine tecemotide was added to standard-of-care neoadjuvant systemic therapy, investigators in Austria found impro...
Not only can palliative care be delivered effectively by telehealth to patients with advanced non-small cell lung cancer, it’s also as effec...